Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom
Launched by MEIR MEDICAL CENTER · May 17, 2010
Trial Information
Current as of May 20, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed more than one bottle per month within a year prior to initiation of the study.
- Exclusion Criteria:
- • Patients younger than 18 years,
- • Patients with severe manual disabilities,
- • Patients with impaired cognition and mentality.
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials